Literature DB >> 16944117

Transport studies with 5-aminosalicylate.

Hua-Wen Xin1, Matthias Schwab, Ulrich Klotz.   

Abstract

OBJECTIVE: It is generally accepted that 5-aminosalicylate (5-ASA; mesalamine), widely used in inflammatory bowel disease therapy, exerts its action from the intraluminal site of the intestine. In addition to local metabolism of 5-ASA, it has been assumed that therapeutic mucosal concentrations of 5-ASA depend on transporter-mediated secretion back to the lumen.
METHODS: We tested the hypothesis that 5-ASA represents a substrate of P-glycoprotein (P-gp) and/or multidrug resistance-associated protein 2 (MRP2), thereby possibly contributing to variable therapeutic effects. Polarized, basal-to-apical transport of [(3)H]5-ASA was studied in monolayers of Caco-2 and L-MDR cells, both of which express P-gp in their apical membrane, as well as in MDCK cells transfected with human MRP2. Moreover, we investigated the influence of 5-ASA on transport of digoxin in Caco-2 cells.
RESULTS: In Caco-2 cells a P-gp-mediated efflux of 5-ASA (5-500 muM) could be excluded. Likewise, in L-MDR1 and MRP2 cells no transport differences in either the basal-to-apical or apical-to-basal direction were measurable. 5-ASA (50 muM to 5 mM) had no effect on the transport of digoxin.
CONCLUSION: From these in-vitro experiments one can conclude that intestinal secretion of 5-ASA is apparently not mediated by P-gp or MRP2. Further studies are needed to identify the nature of the involved active carrier system(s).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16944117     DOI: 10.1007/s00228-006-0182-3

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Mechanisms of transport and structure-permeability relationship of sulfasalazine and its analogs in Caco-2 cell monolayers.

Authors:  E Liang; J Proudfoot; M Yazdanian
Journal:  Pharm Res       Date:  2000-10       Impact factor: 4.200

2.  High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy.

Authors:  R J Farrell; A Murphy; A Long; S Donnelly; A Cherikuri; D O'Toole; N Mahmud; P W Keeling; D G Weir; D Kelleher
Journal:  Gastroenterology       Date:  2000-02       Impact factor: 22.682

3.  Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells.

Authors:  P Artursson; J Karlsson
Journal:  Biochem Biophys Res Commun       Date:  1991-03-29       Impact factor: 3.575

4.  Differences in P-glycoprotein-170 expression and activity between Crohn's disease and ulcerative colitis.

Authors:  B Yacyshyn; W Maksymowych; M B Bowen-Yacyshyn
Journal:  Hum Immunol       Date:  1999-08       Impact factor: 2.850

5.  Intestinal metabolism and transport of 5-aminosalicylate.

Authors:  S Y Zhou; D Fleisher; L H Pao; C Li; B Winward; E M Zimmermann
Journal:  Drug Metab Dispos       Date:  1999-04       Impact factor: 3.922

6.  P-glycoprotein-170 inhibition significantly reduces cortisol and ciclosporin efflux from human intestinal epithelial cells and T lymphocytes.

Authors:  R J Farrell; M J Menconi; A C Keates; C P Kelly
Journal:  Aliment Pharmacol Ther       Date:  2002-05       Impact factor: 8.171

7.  Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4.

Authors:  Rajinder K Bhardwaj; Hartmut Glaeser; Laurent Becquemont; Ulrich Klotz; Suresh K Gupta; Martin F Fromm
Journal:  J Pharmacol Exp Ther       Date:  2002-08       Impact factor: 4.030

8.  Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa?

Authors:  Fuxing Tang; Kazutoshi Horie; Ronald T Borchardt
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

Review 9.  Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease?

Authors:  G-T Ho; F M Moodie; J Satsangi
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

10.  Delivery and fate of oral mesalamine microgranules within the human small intestine.

Authors:  P H Layer; H Goebell; J Keller; A Dignass; U Klotz
Journal:  Gastroenterology       Date:  1995-05       Impact factor: 22.682

View more
  1 in total

1.  TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs.

Authors:  Kavitha S Rao; Maram K Reddy; Jayme L Horning; Vinod Labhasetwar
Journal:  Biomaterials       Date:  2008-08-28       Impact factor: 12.479

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.